GlassScriptPhysician profile
Christopher R Carter
NPI 1003814799
$4,120.78
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $255 · 2021: $270 · 2022: $789 · 2023: $853 · 2024: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539 · Education: $92.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.18 |
| Education | $92.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,089.21 | 2019-2024 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $892.09 | 2019-2024 | Rinvoq, Skyrizi |
| Gilead Sciences, INC. | $629.13 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $498.76 | 2021-2023 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $280.25 | 2019-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.42 | 2019-2023 | Xifaxan |
| Daiichi Sankyo INC. | $106.94 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $90.51 | 2022 | |
| Celgene Corporation | $75.65 | 2022-2024 | Zeposia |
| Genzyme Corporation | $70.90 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $37.89 | 2024 | Voquezna |
| Organon LLC | $22.07 | 2023 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Shire North American Group INC | $14.81 | 2019 | |
| Pfizer INC. | $14.42 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.